No Data
Shanghai Pharmaceuticals Secures Approval for Production of Pain, Inflammation Capsule
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
sh pharma (601607.SH): Approval granted for the production of Selamectin capsules.
Sh Pharma (601607.SH) announced on August 6th that its controlled subsidiary, Changzhou Pharmaceutical Factory Co., Ltd. (referred to as 'Changzhou Pharmaceutical Factory') received the Drug Registration Certificate (Certificate No. 2024S01765) issued by the State Drug Administration for Celecoxib capsules (referred to as 'the pharmaceutical'), which has been approved for production. Celecoxib capsules are COX-2-specific inhibitors that inhibit the production of prostaglandins by inhibiting cyclooxygenase-2 (COX-2) and are also the world's first selective non-steroidal anti-inflammatory analgesic drug (NSAIDs).
Shanghai Pharmaceuticals Unit's Methylcobalamin Tablets Passes Drug Regulator's Evaluation
Sh Pharma (601607.SH): The consistency evaluation of Mecobalamin tablets for generic drugs has been approved.
Sh Pharma (601607.SH) announced that its holding subsidiary, Shanghai Xinya Pharmaceutical Co., Ltd. in Minhang, has recently...
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't AppealingNo Data
